The capsular part of the central amygdala (CeC) is called the ''nociceptive amygdala,'' as it receives nociceptive information from various pathways, including monosynaptic input from the lateral part of the parabrachial nucleus (LPB), a major target of ascending neurons in the spinal and medullary dorsal horn. LPB-CeC synaptic transmission is mediated by glutamate but the fibers from the LPB also contain calcitonin gene-related peptide (CGRP) and the CeC is rich in CGRP-binding sites. CGRP might be released in response to strong nociception and activate these CGRP receptors. Though it has been shown that CGRP affects the excitatory postsynaptic current (EPSC) amplitude at this synapse in a manner sensitive to NMDA receptor (NMDA-R) blockers, the effect of CGRP on postsynaptic NMDA-R-mediated current recorded in isolation has never been directly examined. Thus, we evaluated the effects of CGRP on NMDA-R-mediated EPSCs that were pharmacologically isolated in brain slices from naïve mice. CGRP significantly increased the amplitude of EPSCs mediated by NMDA-Rs in a manner dependent on protein kinase A activation, but not that mediated by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, in concentration-dependent and antagonist-sensitive manners. This CGRP-induced potentiation of synaptic NMDA-R function would have a potent impact on the strengthening of the nociception-emotion link in persistent pain.
Background
Nociceptive signals arising from peripheral nociceptors excite ascending neurons in the spinal dorsal horn and spinal nucleus of the trigeminal nerve. The most notable target of the projections from these ascending nociceptive neurons is the lateral part of the parabrachial nucleus (LPB), 1 and the neurons in the LPB then monosynaptically project to the central nucleus of the amygdala (CeA), especially its capsular part (CeC). 2 Because of this direct nociceptive input, which bypasses the thalamocortical route, and of the subsequent neuronal excitation, the CeC is called the ''nociceptive amygdala.'' 3, 4 Synaptic transmission at this LPB-CeC synapse is principally glutamatergic 2 and shows robust potentiation in various types of animal models of semi-acute to chronic pain, including nerve injury-induced neuropathic pain, 5 streptozotocin-induced neuropathic pain, 6 arthritis pain, 7 visceral pain, 8 muscle pain, 9 and formalin-induced inflammatory pain.
only poorly identified. 13 The LPB is one of the sites with the densest CGRP expression and the CeA is one of the sites with the most CGRP-binding sites and highest CGRP1 receptor expression.
14-17 CGRP-containing terminals arising from the LPB mostly form asymmetrical synapses with CeC neurons 18, 19 , and optogenetic activation of these terminals gives rise to monosynaptic postsynaptic responses in CeC neurons, 2 which form most monosynaptic LPB-CeC projections underlying nociception-induced threat learning. 20, 21 Functionally, microinjection of CGRP1-R antagonists into the CeA of arthritic rats attenuates pain-related behaviors and noxious stimulation-induced responses of CeC neurons. 7 In line with this, application of CGRP antagonists attenuates the potentiated LPB-CeC synaptic transmission in slices acutely prepared from arthritic rats, 7 suggesting that activation of CGRP1-Rs in CeC neurons by CGRP released from the LPB-CeC terminals would play a role in LPB-CeC synaptic potentiation in arthritic rats. In addition, in slices from naı¨ve rats, the LPB-CeC synaptic transmission is potentiated by application of exogenous CGRP. 22 Han et al. 22 attributed the increased excitatory postsynaptic current (EPSC) amplitude after CGRP application to attenuation of the outward rectification property of N-methyl-D-aspartate (NMDA) receptors (NMDA-Rs), resulting in a detectable NMDA receptor-mediated current even at a near-resting holding potential that would otherwise be faint because of its ''Mg 2þ -block'' property. However, they did not examine whether the NMDA-R-and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated components at the LPB-CeC synapse recorded in isolation are affected by CGRP. This information is necessary to understand the nature of the effect of CGRP on LPB-CeC synaptic transmission. A recent study indicated that the NMDA-R-mediated synaptic transmission between the basolateral amygdala (BLA) and the CeA is potentiated by CGRP in rat. 23 In this study, we examined whether CGRP affects NMDA-Rmediated postsynaptic currents without affecting AMPA-R-mediated currents at LPB-CeC synapses in isolated brain slices prepared from naı¨ve mice.
Materials and methods

Preparation of transverse brain slices
The protocols of the animal experiments were reviewed and approved by the Institutional Animal Care and Use Committee of Jikei University and conformed to the Guidelines for the Proper Conduct of Animal Experiments of the Science Council of Japan (2006) . Transverse slices containing the amygdala from male C57BL/6J mice (14-40 days old) were prepared according to methods described previously. 5, 24, 25 Briefly, a transverse block of the forebrain containing the amygdaloid complex was dissected out and cut at the midline. 
Patch-clamp recordings
Neurons in the CeC were visually identified under an upright microscope (BX-50WI and BX-51WI; Olympus). Whole-cell transmembrane current was recorded from neurons in the CeC of either side. Patchclamp electrodes were made from borosilicate glass pipettes (1B120F-4; World Precision Instruments). The compositions of the internal solutions were (in mM) as follows: (1) for recordings at a fixed holding potential (À60 mV): 120 K-gluconate, 6 NaCl, 1 CaCl 2 , 2 MgCl 2 , 12 Na 2 phosphocreatine, 2 Mg ATP, 0.5 Na GTP, 5 EGTA, and 10 HEPES 1/2Na (pH 7.2 as adjusted with KOH; osmolality; about 300 mOsm/kg); and (2) for plotting the I-V curve of the EPSC NMDA : 136 CsCl, 1 CaCl 2 , 2 Mg ATP, 5 EGTA, 12 Na 2 phosphocreatine, 10 HEPES 1/2Na, and 5 QX-314 (pH 7.3 as adjusted with CsOH; osmolarity, about 300 mOsm/kg). With these solutions, the tip resistance of the electrode was 4-10 MV. The evoked EPSC NMDA or EPSC AMPA were recorded at a holding potential of À60 mV, except during the I-V curve experiments. The input resistance, resting membrane potential, and whole-cell capacitance were measured immediately after the establishment of whole-cell mode by membrane rupture. The membrane response to a rectangular pre-pulse delivered before afferent stimulations was continuously recorded and recordings with fluctuations of series resistance larger than about 30% were discarded. For the I-V curve experiments, the EPSC NMDA was recorded at holding potentials from À70 mV to þ35 mV with the protocol described below. Membrane currents were recorded using a Axopatch 200B and a Multiclamp 700B amplifier (Molecular Devices), low-pass filtered at 2 kHz, and digitized at 10 kHz and with a 16-bit resolution with a PowerLab interface (ADInstruments).
All recordings were made at room temperature (about 25 C). All compounds except those noted were purchased from Sigma-Aldrich Japan (Tokyo, Japan), Wako Pure Chemical Industries (Osaka, Japan), and Nacalai Tesque (Kyoto, Japan).
Estimation of the I-V relationship of the EPSC NMDA
The protocol used to estimate the I-V relationship of the EPSC NMDA is illustrated in Figure 3(a.1) . First, the membrane potential of neurons was held at À70 mV for 10 s and a pre-pulse (PP, arrow; 50 ms, À5 mV) was delivered to measure relative changes in membrane properties. After a pause of 200 ms, four pulses of electrical stimulation were delivered with 10-s intervals. The four responses to each of these stimuli were used to calculate the average wave form of the EPSC NMDA . After a pause of 5 s following the last stimulation, the membrane potential (V m ) was gradually depolarized to À35 mV for 20 s and kept at À35 mV. A pause of 10 s was given at À35 mV before starting the four stimuli. This epoch composed of 10-s pause, 4 stimuli at 10-s interval (shown as short vertical bars in Figure 3 (a.1)), and 5 s pause after the last stimulus was repeated at À35, 0, and þ35 mV with gradual shift of the holding potential from 1 s to another for 20 s inbetween. After the last stimulation at þ35 mV, the V m was slowly shifted back to À70 mV for 30 s. Single episode of voltage clamps and stimulations took 280 s and repeated every 5 min. Thus, the EPSC NMDA waveforms (average of 4 consecutive responses) at À70 mV, À35 mV, 0 mV, and þ35 mV were obtained every 5 min.
Afferent pathway stimulation
A bipolar steel electrode (interpolar distance, approximately 100 mm; Unique Medical, Tokyo, Japan) was carefully placed on the fiber tract ventromedial to the CeC under microscopic control to stimulate the LPB pathway, and the stimulation intensity was set so that the EPSC AMPA amplitude became approximately 100 pA before CNQX application. The resulting stimulation intensity was 0.1-1 mA (average, 0.62 mA). The pulse duration was 100 ms. During the EPSC AMPA recordings, double pulses with an inter-stimulus interval of 100 ms were delivered to calculate the paired-pulse ratio (PPR) of the EPSC AMPA amplitude by normalizing the amplitude of the second one by that of the first one. 5 
Drug application
CGRP and BIBN4096BS, a selective non-peptide CGRP1 receptor antagonist, 26 were dissolved in ACSF. BIBN4096BS was a kind gift from BoehringerIngelheim, Japan. KT5720 was obtained as a solution at 10 mM in DMSO (Tocris, Bristol, UK) and dissolved in ACSF at the final concentration (1 mM). For the CGRP application in the presence of KT5720, CGRP solution (500 nM) was made with the ACSF containing KT5720 at 1 mM.
Data and statistical analysis
The recorded membrane current was analyzed off-line with Igor Pro 6 (WaveMetrics, OR, USA) using procedures written by FK. Peak amplitude was measured on the basis of the averaged waveform of the evoked EPSCs (average times are noted for each result). Values are expressed as mean values AE standard error of the mean. Differences in values were compared using one-way analysis of variance (ANOVA) followed by a post hoc test (Gabriel test) two-way ANOVA, Student's t test, or Mann-Whitney U test. Differences with a probability (P) less than 0.05 were considered significant.
Results
CGRP increases the EPSC NMDA with a slow time course
First, we applied 500 nM CGRP onto slices containing the CeC for 20 min while recording the postsynaptic NMDA receptor-mediated current (EPSC NMDA ) in response to LPB pathway stimulation. The NMDA component was pharmacologically isolated by the addition of CNQX (10 mM) and picrotoxin (100 mM) and the membrane potential was kept at À60 mV in the presence of 2 mM Ca 2þ and 0 mM Mg 2þ . This ACSF solution was perfused for more than 10 min before the application of CGRP. At the end of the recording, APV (50 mM) was applied to confirm the NMDA-R-mediated current.
Application of CGRP (500 nM) slowly increased the amplitude of the EPSC NMDA (Figure 1 The changes in the EPSC NMDA amplitude for 12 neurons after 20-min application of CGRP followed by 10-min washout are summarized in Figure 1(d) . Based on the 99% confidence limit (horizontal dotted line in Figure 1(d) ) of the ''Control'' effects (black open circles), we classified the neurons as ''responders'' to CGRP (blue circles in Figure 1(d) ) or ''non-responders'' (red circles in Figure 1(d) ). There was significant difference (P < 0.01; one-way ANOVA with post hoc Gabriel test) between the mean EPSC NMDA amplitudes for responders and control (0 CGRP) but not between those for the control and non-responders.
We then examined the effect of CGRP (500 nM) in the presence of protein kinase A (PKA) inhibitor KT5720 (1 mM), which was applied from 15 to 20 min before the application of CGRP and present in the ACSF during whole span of recording. The X markers in Figure 1 (d) indicate EPSC NMDA amplitude after 10 min wash after 20 min application of CGRP as with the data shown with open circles but recorded in the presence of KT5720. There were significant differences (P < 0.01; one-way ANOVA with post hoc Gabriel test) between the mean EPSC NMDA amplitude for responders and that recorded in the presence of KT5720 but not between that for the non-responders and that recorded in the presence of KT5720 (Figure 1(d) ). These results suggest activation of PKA plays a significant role in the effect of CGRP in augmenting EPSC NMDA .
Figure 1(e) shows the time course of the EPSC NMDA amplitude of responders (blue circles) and nonresponders (red circles) to 500 nM CGRP (horizontal bar) and to control solution (black circles). One-way ANOVA analysis indicated that there were significant differences between these three groups at every time point after 15 min (F(2,20) ¼ 4.48 and P ¼ 0.025 for 15 min and F(2,17) ¼ 5.76 and P ¼ 0.012 for 50 min (recording was discontinued before 50 min for two neurons in the control group and one neuron in the nonresponder group); P < 0.05 at all other time points), and post hoc analysis (Gabriel test) indicated that there were significant differences between the EPSC NMDA amplitudes in responder neurons and control and non-responder neurons after 15 min (P ¼ 0.044 and 0.042 at 15 min; P ¼ 0.020 and 0.032 at 50 min; P < 0.05 at all other time points; Gabriel test). These were designated ''responding'' and ''non-responding'' neurons, respectively. The increased EPSC NMDA amplitude in responding neurons did not recover after 30 min of washout (Figure 1(e) ) and was still increasing (Figure 1(e) ). Unlike the impression from the representative traces in Figure 1(a.1) and (a.2) , the amplitude and decay kinetics of the EPSC NMDA were not apparently related to the difference in responses to CGRP in each neuron. There were no significant differences in the peak amplitude and decay kinetics between these two groups (peak amplitude, 25.3 pA AE 15.3 pA and 40.5 AE 19.2 pA (P ¼ 0.22; Mann-Whitney U test); decay time constant, 75.7 ms AE 41.6 ms and 64.5 ms AE 28.8 ms (P ¼ 0.75; Mann-Whitney U test) for responders (n ¼ 6) and non-responders (n ¼ 6), respectively).
Interestingly, the EPSC NMDA amplitude increased slightly but significantly during the course of recording with low Mg 2þ concentration (0 mM for data in Figure  1 and 0.1 mM for data in Figure 2 ). This increase was significant between the amplitude at time 0 (Figure 1 (e) and 2(a)) and that at any time point thereafter (point-topoint comparison with Mann-Whitney U test; P < 0.05). As such gradual increase in EPSC NMDA amplitude was similarly observed even in the 0 CGRP groups and was not observed with EPSC AMPA (Figure 4(c) ), it is unlikely that this increase resulted from the CGRP effect but rather it might have resulted from repeated activation of NMDA-Rs in the environment containing low concentration of Mg 2þ . The mechanism underlying this increase was not further examined.
The increase in the EPSC NMDA amplitude by CGRP is concentration-dependent and mediated by CGRP1 receptors , a low Mg condition almost similar to that used for the experiments in Figure 1 . In this experiment, we did not distinguish responders and non-responders and simply compared pooled responses to applications of control (i.e., 0 nM CGRP), 100 nM, 250 nM, and 500 nM CGRP for 20 min. To identify the type of receptors involved in the effects of CGRP, we compared the effects of CGRP on the EPSC NMDA amplitude recorded in isolation at À60 mV with 0.1 mM Mg 2þ between CGRP applied in the presence and absence of non-peptide CGRP1-R antagonist. BIBN4096BS (1 mM) was bath-applied for 10 min before the application of 500 nM CGRP solution, which also contained the same concentration of the antagonist (Figure 2(b.1) ). In the presence of BIBN4096BS, CGRP only slightly affected the EPSC NMDA (Figure 2(b.2) ). There was a significant difference in the EPSC NMDA amplitude with CGRP between that in the presence and absence of BIBN4096BS after 5 min and 10 min of CGRP application (*P < 0.05; Mann-Whitney U test; Figure 2(b.2) ). An interesting observation with this 10-min application of 500 nM CGRP (Figure 2(b.2) ) compared with the 20-min application (Figure 2(a.2) ) was that the sustained increase in EPSC NMDA even after >20 min washout was not manifested with the 10-min application. It is therefore possible that the prolonged potentiating effect of CGRP on EPSC NMDA might depend on the CGRP has little effect on the current-voltage relationship of the EPSC NMDA CGRP increases the amplitude of the EPSC recorded as a mixture of the EPSC AMPA and EPSC NMDA . 22 In that study, it was interpreted that CGRP attenuated the outwardly rectifying properties of NMDA-Rs (i.e., ''Mg 2þ -block'' at hyperpolarized potentials) such that significant EPSC NMDA components became large enough to be observed as an inward current similar to EPSC AMPA , even in the presence of 1.2 mM Mg 2þ at À60 mV. 22 However, the effect of CGRP on the I-V relationship of the EPSC NMDA has never been directly assessed in 2) The time course of the EPSC NMDA amplitude (top, measured at a V H of þ35 mV (relative to the EPSC NMDA amplitude at a V H of þ35 mV at pre-CGRP); middle, that at À35 mV; bottom, the absolute value of the ratio of the EPSC NMDA amplitude at À35 mV to that at þ35 mV). CGRP (500 nM) was applied from around 0 min for 20 min (note that the timing for obtaining EPSC NMDA s for distinct holding potentials deviates from the time shown in Figure 3 (b.2) by $2 min at the maximum due to the sequential sampling of the data; Figure 3(a.1) ). The EPSC NMDA was recorded with ''standard Mg ACSF'' containing 1.3 mM Mg 2þ . The black arrowhead shows the relative EPSC NMDA current at þ35 mV before CGRP application with which all other amplitudes are normalized. isolation at the LPB-CeC synapse. To directly address this issue, the LPB fibers were repeatedly stimulated at different holding potentials (-70 mV, À35 mV, 0 mV, and þ35 mV) four times at 10-s intervals to get the average response at each holding potential (see Methods and Materials section and Figure 3(a.1) ) in ACSF solution containing 1.3 mM Mg 2þ . This external solution allows the appearance of the typical outward rectification of the NMDA-R current. Using the averaged waveform of the EPSC NMDA at four different holding potentials recorded in the presence of CNQX (10 mM), we measured the amplitude of the EPSC NMDA at 200 ms from the stimulus (vertical dotted lines in Figure 3(a.2) ) to construct the I-V curve of the synaptically activated NMDA-R responses. Figure 3(a.3) indicates the I-V curve constructed from the representative responses in Figure 3(a.2) . Despite an increase in the EPSC NMDA amplitude at þ35 mV, there was no apparent change in its amplitude at À70 mV. Figure  3(b) summarizes the voltage-dependency of the EPSC NMDA . Figure 3(b.1) shows the mean normalized EPSC NMDA amplitude during the course of CGRP (500 nM) application. This normalized EPSC NMDA amplitude was obtained by dividing the EPSC NMDA amplitude by that before CGRP application recorded at þ35 mV. As shown in Figure 3(b.2) , despite a significant increase in the normalized EPSC NMDA amplitude at þ35 mV at 15 min after application (top curve: P < 0.05; Mann-Whitney U test, vs. Pre-CGRP; n ¼ 10 neurons), there was almost no changes in the I À35 /I þ35 , a rectification index calculated to evaluate the changes in the outward rectification properties of the EPSC NMDA (the curve at the bottom; P > 0.05). These results indicate that CGRP increases the EPSC NMDA 
CGRP does not affect the EPSC AMPA amplitude
It is most likely that the increase in the EPSC NMDA amplitude induced by CGRP resulted from a direct effect on NMDA-R functions. However, such an increase would also occur through (1) an increased release of glutamate, (2) decreased intracleft clearance of glutamate, or (3) any other changes resulting in a general increase in glutamatergic signaling (e.g., an increase in energy supply 27 ). To examine these possibilities, we analyzed the effect of CGRP on the AMPA receptor-mediated EPSC (EPSC AMPA ). The EPSC AMPA was recorded in isolation in ACSF containing 1. These EPSC AMPA components were mediated by postsynaptic AMPA receptors because CNQX completely abolished this component (Figure 4(a), (b) , and (c); CNQX). Also, the PPR of the EPSC AMPA amplitude in response to paired stimulation at an interval of 100 ms was not affected by CGRP (Figure 4 (a) and (d); paired t test). These results indicate that CGRP does not affect postsynaptic AMPA receptors and the glutamate release probability; rather, it is likely that this increase in the EPSC NMDA resulted from a direct enhancing effect of CGRP on NMDA-Rs.
Discussion
The LPB is the site with the highest expression of CGRP in the whole brain, and the CeA, particularly the CeC and CeL, has a very high density of terminals containing CGRP in mice and rats. 16, 18 CGRP-binding sites are also rich in the CeA. 15 These terminals arising from the LPB form asymmetric synapses at the dendritic shafts of CeC neurons. 18, 19 Thus, it is postulated that co-released CGRP would modulate excitatory synaptic transmission at these LPB-CeC synapses. In agreement with this, it has been shown that exogenous application of CGRP increases the amplitude of the LPB-CeC EPSC recorded as a mixture of AMPA-R-and NMDA-R-mediated currents at À60 mV, and this increase was not observed in the presence of APV. 22 However, it remained unclear whether CGRP could affect the NMDA-R-mediated current itself, because the recordings in their report comprised a mixture of these two types of glutamate receptor-mediated currents.
In the present study, we have clearly demonstrated that exogenously applied CGRP significantly increases the amplitude of the EPSC NMDA recorded in isolation at the LPB-CeC synapses in a dose-dependent manner. This increase was characterized by the following: (1) it was observed in the absence of Mg 2þ block, unlike in the report by Han et al.; 22 (2) it was inhibited by a CGRP1 receptor antagonist; (3) it continued to develop slowly even after the agonist washout particularly after longer application; (4) this increase was significantly attenuated when activation of PKA is inhibited, thus suggesting an involvement of PKA-dependent process; (5) it was not accompanied by a significant change in the voltage dependency of the EPSC NMDA recorded in the presence of 1.3 mM Mg 2þ ; and (6) CGRP exerted no effects on the amplitude of the EPSC AMPA and release probability of glutamate from the terminal of LPB fibers. Such selective enhancement of NMDA-R-mediated components might play a role in the activity-dependent potentiation of LPBCeC synapses observed in chronic pain models. 2, 5, 6, 8, 24 CGRP affects NMDA receptor function A recent study indicated that exogenous CGRP increases the current through subsynaptic NMDA receptors at BLA-CeA synapses. 23 The present study adds a novel finding that CGRP induces synaptic potentiation not only at the BLA-CeA synapse but also at the LPB-CeC synapse in a manner, at least partly, dependent on PKA activation. This finding is of interest because (1) the BLA-CeA projection itself does not contain CGRP 18 and (2) we have demonstrated that both BLA-CeA and LPB-CeC pathways show manifest synaptic potentiation following fear/threat learning. 25 A plausible scenario is that the activation of CGRP1-Rs by CGRP released from the LPB terminals affects NMDA-Rs expressed in the same neurons through unidentified intracellular mechanisms. It is therefore an interesting future project to directly demonstrate whether CGRP is indeed released from the stimulated terminals with the stimulation pattern used in this study to stimulate glutamate release or CGRP is released only in response to specific stimulation pattern or intensity.
The CGRP1-Rs are formed as a heterodimeric complex composed of a G protein-coupled receptor and an accessory protein RAMP1 and are usually coupled with G s proteins. Thus, activation of CGRP receptors increases cAMP production and activates protein kinase A. As the increase in the isolated NMDA-Rmediated EPSC amplitude by CGRP in the absence of Mg 2þ blockade in the present study was significantly attenuated by PKA inhibition in a similar manner to the reported PKA-dependent increase in the EPSC amplitude that was dependent on Mg 2þ block relief, 22 both effects are likely to be downstream to the G s -mediated activation of PKA by CGRP1-R stimulation. Notably, PKA activation or phosphorylation leads to increased channel opening probability and increased subsynaptic membrane trafficking of NMDA receptors. [28] [29] [30] This positive regulation of NMDA-R function by CGRP is in agreement with the increase in the EPSC NMDA amplitude in this study.
Han et al. 22 attributed the increase in the amplitude of the EPSC recorded as a mixture of AMPA-R-and NMDA-R-mediated components by CGRP at the LPB-CeC synapse to the decreased rectification of PKC-activated NMDA-R reported in trigeminal neurons and faster kinetics of NR1/NR2C receptors in heterologously expressed NMDA-Rs with a phosphorylation-mimicking point mutation. 31, 32 However, the CGRP-sensitive EPSC NMDA observed in the present study showed much slower rise and decay kinetics than the EPSC AMPA both before and after CGRP application, making it unlikely that the EPSC NMDA becomes indistinguishable from EPSC AMPA , even after CGRP application. Of note, Wu et al. 23 attributed the long-lasting synaptic potentiation of the field EPSP slope of BLA-CeA transmission after the application of CGRP in slices to a secondary effect of the CGRP-induced enhancement of postsynaptic NMDA currents.
Although it remains to be demonstrated whether such potentiation also occurs at LPB-CeC synapses, a possible cause of the increase in the EPSC amplitude reported in a previous paper 23 would be such NMDA-R-dependent secondary potentiation of AMPA-R function. In addition to this possibility, the differences in the experimental conditions, such as the difference in the species, the recording temperature and the age of the animals, would also underlie the differences between our data and those of the previous report. 22 However, the absence of the change in the EPSC AMPA amplitude following CGRP application commonly observed in the study by Han et al. 22 (recording at 31 C), by Wu et al. 23 (at room temperature), and in this study (at room temperature) would suggest that the lower temperature used in this study and that by Wu et al. 23 would not resulted in the absence of this CGRP effect.
Functional significance of the synaptic modulation by CGRP
The behavioral effect and roles of CGRP in the amygdala complex remain controversial. Han et al. 22 reported that intra-CeA injection of CGRP in awake rats augments nociception-induced responses. In contrast, CGRP microinjected into the CeA 33 and BLA 17 of anesthetized rats exerts analgesic effects. Because the CeA is mostly composed of inhibitory neurons, which are mutually interconnected to form a circuit with complex feedforward and feedback inhibitions (discussed in Ehrlich et al. 34 and Sugimura et al. 2 ), the final behavioral outcomes of intra-CeA CGRP-R stimulation would largely depend on the role of the subpopulation of neurons activated by CGRP. In agreement with this, we have recently demonstrated that despite the presence of monosynaptic EPSC in response to selective optogenetic stimulation of the LPB fibers in almost all neurons in the CeC, as confirmed by optogenetic activation of the presynaptic terminals, only the neurons with late-firing properties show potentiated EPSCs at 24 h after intraplantar formalin injection. This suggests that the synaptic plasticity in response to sustained intensive nociceptive inputs is not shared by all of the LPB-CeC synapses.
In conclusion, it is likely that CGRP in the CeA is a peptidergic modulator of synaptic plasticity. Pharmacological intervention in this CGRP system in the CeA would have therapeutic potential for improving fear-/threat-related emotional disorders such as posttraumatic stress disorder 23 but also emotional complications in persistent pain. 35 
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